Forty years of cisplatin-based chemotherapy in muscle-invasive bladder cancer: are we understanding how, who and when?

Schardt, Julian; Roth, Beat; Seiler, Roland (2019). Forty years of cisplatin-based chemotherapy in muscle-invasive bladder cancer: are we understanding how, who and when? World journal of urology, 37(9), pp. 1759-1765. Springer-Verlag 10.1007/s00345-018-2544-8

[img] Text
Ro_forty years of cisplatin-based chemotherapy in muscle-invasive bladder cancer - are we understanding how, who and when_261118.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (667kB) | Request a copy

PURPOSE For 40 years cisplatin-based chemotherapy has been administered to patients with muscle-invasive bladder cancer (MIBC). The best evidence of its efficacy is found in the context of neoadjuvant chemotherapy (NAC). However, the benefit to the patient is modest, with an improvement in 5-year overall survival of only 5-8%. Approximately 60% of patients still have muscle-invasive disease at cystectomy despite NAC. Selecting patients based on the likelihood of response appears to be a promising strategy to improve on this modest benefit. To realize this promise, researchers are investigating biomarkers for identifying responders and non-responders prior to NAC. METHODS In this review, we discuss a number of tissue- and liquid-based biomarkers associated with the response to NAC. RESULTS AND CONCLUSIONS We elaborate biomarkers at the methylation, DNA, RNA and protein levels and give their current status in clinical trials and/or their implementation in daily clinical practice. In particular, detection of alterations in DNA damage repair pathways as well as molecular subtypes seems to be a promising method for identifying responders to NAC. Furthermore, we illustrate liquid-based biomarkers. Circulating tumor DNA (ctDNA) in patient blood and urine appear to offer an elegant way for biological characterization of MIBC. Recent data show that the presence of ctDNA is limited in patients with localized MIBC being considered for NAC. At this disease stage, ctDNA in patient urine may be more promising for the genomic characterization of MIBC. However, ctDNA in blood or urine has not yet been rigorously investigated in this clinical context.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Urology

UniBE Contributor:

Schardt, Julian; Roth, Beat and Seiler, Roland

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0724-4983

Publisher:

Springer-Verlag

Language:

English

Submitter:

Jeannine Wiemann

Date Deposited:

30 Nov 2018 08:00

Last Modified:

23 Oct 2019 12:12

Publisher DOI:

10.1007/s00345-018-2544-8

PubMed ID:

30392011

Uncontrolled Keywords:

Cisplatin resistance Gene expression analysis Molecular subtypes Muscle-invasive bladder cancer Neoadjuvant chemotherapy Second-line treatment

BORIS DOI:

10.7892/boris.121694

URI:

https://boris.unibe.ch/id/eprint/121694

Actions (login required)

Edit item Edit item
Provide Feedback